All In Biotech

Drug Trial Radar · NCT07915245

A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it. The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.

Conditions

  • Obesity
  • Overweight

Interventions

  • LY4247147Drug

    administered SC

  • LY4247147Drug

    administered IV

  • PlaceboDrug

    administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through End of the Follow-up (Estimated as Week 25)
  2. Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through End of the Follow-up (Estimated as Week 33)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • ICON Early Phase Services Lenexa Center

    Lenexa, Kansas · Recruiting

  • ICON

    Salt Lake City, Utah · Not yet recruiting

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.